Lei Tian et al.: JAMA Ophthalmol. Published online March 16, 2023. doi:10.1001/jamaophthalmol.2023.0270
Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial
Tauber et al.: Ophthalmology 2022 December, published Ahead of Print
NOV03 for Dry Eye Disease Associated With Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study
Jacobi et al.; Journal of Ocular Pharmacology and Therapeutics 2022 May, Publish Ahead of Print
A Water-Free Omega-3 Fatty Acid Eye Drop Formulation for the Treatment of Evaporative Dry Eye Disease: A Prospective, Multicenter Noninterventional Study
Sheppard et al.; Cornea 2021; Jan; Publish Ahead of Print.
Results of the Randomized Phase 2B/3 ESSENCE study with CyclASol 0.1% for treatment of dry eye disease
Tauber et al.; Cornea 2020 Dec 22; Publish Ahead of Print.
Randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease
Hyeck-Soo Son et al.; Journal of Refractive Surgery 2020; 36: 474-480
Semi-fluorinated Alkane Eye Drops Reduce Signs and Symptoms of Evaporative Dry Eye Disease After Cataract Surgery
Doreen Schmidl et al.; Journal Ocular Pharmacology and Therapeutics 2020; 36: 154-161
Influence of Perfluorohexyloctane Eye Drops on Tear Film Thickness in Patients with Mild to Moderate Dry Eye Disease: A Randomized Controlled Clinical Trial
Agarwal et al.; Eur. Pharm. Biopharm 2019; 142:83-91
Topical semifluorinated alkane-based azithromycin suspension for the management of ocular infections
Agarwal et al; OcularSurface 2019
Preclinical Studies Evaluating the Effect of Semifluorinated Alkanes on Ocular Surface and Tear Fluid Dynamics
Eberwein et al.; Ophthalmic Res 2019
Semifluorinated Alkane Eye Drops in Chronic Ocular Graft-versus-Host Disease: A Prospective, Multicenter, Noninterventional Study
Wirta et al.; Ophthalmology 2019
A Clinical Phase 2 Study to Assess Efficacy, Safety and Tolerability of CyclASol® for Treatment of Dry Eye Disease (DED)
Agarwal et al.; IntJPharm 2018; 538:119-129
Semifluorinated alkane based systems for enhanced corneal penetratoin of poorly soluble drugs
De Majumdar et al.; CurrMolMed 2017; 17:211-220
A Low concentration of Tacrolismus /Semifluorinate Alkane (SFA) Eyedrop suppresses intraocular inflammation in experimental models of uveitis
Gehlsen et al.; GraefesArchClinExpOphal 2017; 255:767-775
A Semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic options for topical treatment of dry eye
Runnsjoe et al.; JChemThermodynam 2017; 105:352-361
Semifluorinated Alkanes and Alkanes-A Phase Study of the Perfluorohexyloctane – Tetradecane System
Steven et al.; JOculPharmacolTher 2017; 33:678-685
Semifluorinated alkane eye drops for treatment of dry eye disease due to meibomian gland disease
Steven et al.; KlinMonatsblAugenheilkd 2017; 234:662-669
Influence of Aging on Severity and Anti-Inflammatory Treatment of Experimental Dry Eye Disease
Steven et al; JOculPharmacolTher 2015; 31:498-503
Semifluorinated alkane eye drops for treatment of dry eye disease